Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Gérald Raverot"'
Autor:
Marie-Christine Vantyghem, Stéphanie Espiard, Gérald Raverot, Fatimetou Abderrahmane, Cardot Catherine, Hervé Lefebvre, Jérôme Bertherat
Publikováno v:
Journal of the Endocrine Society
Objective: The Carney Complex (CNC) is a multiple endocrine and non endocrine neoplasia, mostly due to PRKAR1A mutations. The PRKAR1A mutation c.709(-7-2)del located in the intron 7 is one of the three known hot spot. The objective of this study is t
Autor:
V. Lapras, Solène Castellnou, Véronique Raverot, Emmanuel Jouanneau, Françoise Borson-Chazot, Gérald Raverot, Hélène Lasolle, Alexandre Vasiljevic, Eudeline Alix
Publikováno v:
Journal of the Endocrine Society
Context. Somatostatin receptor type 5 (SST5), a target of pasireotide, is inconsistently expressed by corticotroph tumors. Somatic driver mutations in the ubiquitin-specific protease 8 (USP8) gene have been describes in 35% to 60% of corticotropinoma
Autor:
E. Sonnet, Thierry Brue, Marie-Laure Raffin-Sanson, Claire Briet, Amandine Ferriere, Philippe Chanson, Frédéric Illouz, Mathilde Munier, Marie-Christine Vantyghem, Patrice Rodien, Gérald Raverot
Publikováno v:
Journal of the Endocrine Society
Background: Somatostatin analogs (SSA) are efficiently used to control central hyperthyroidism in patients with thyrotropin-secreting pituitary neuroendocrine tumor (TSH-PitNET). The aim of this study was to describe the frequency of thyrotropin (TSH
Autor:
Murray B. Gordon, Elena Isaeva, Gary Patou, William H. Ludlam, Shlomo Melmed, Mark E. Molitch, Nina Leonova, Yossi Gilgun-Sherki, Yulia Pokramovich, Asi Haviv, Yury E. Poteshkin, Irina Bondar, Yossi G Strasburger, Gérald Raverot, Elena Grineva, Djuro P Macut, Maria Fleseriu, Nienke Biermasz, Alexander Dreval
Publikováno v:
Journal of the Endocrine Society
Background: MPOWERED, a large phase 3 trial, assessed maintenance of response to oral octreotide capsules (OOC; MYCAPSSA®) compared to injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly who responded to OOC and iSRLs (octre
Autor:
Marie Laure Nunes, Allard L, Carine Courtillot, Christine Cortet-Rudelli, Julie Sarfati, P. Caron, B. Delemer, Jérôme Bertherat, Gérald Raverot, Albarel Loy F, P. Chanson, Dominique Maiter, Sylvie Salenave, Christel Jublanc
Publikováno v:
Journal of the Endocrine Society
Dopamine agonists (DAs), which are used as first line therapy in patients with macroprolactinomas, and antipsychotics have opposite effects on D2 dopamine receptors. In patients with severe psychiatric conditions treated with antipsychotics, the rare
Autor:
Federico Campigotto, Marie Bex, Mônica R. Gadelha, Amy Bartalotta, Ricardo Maamari, Annamaria Colao, Gérald Raverot
Publikováno v:
Journal of the Endocrine Society
Background: In a 24-week, Phase 3 study (PAOLA), long-acting pasireotide demonstrated superior efficacy (GH 1.3xULN) despite ≥3 months of treatment with maximal approved doses of long-acting octreotide/lanreotide received open-label long-acting pas